Improvement in facial/total Vitiligo Area Scoring Index seen with continued treatment from weeks 52 to 104.
News and Features
Significantly increased risk seen for adults with moderate-to-severe versus mild atopic dermatitis.
Retifanlimab is a programmed death receptor-1-blocking antibody.
The approval of the new citrate-free, high-concentration formulation was based on data from a phase 1 pharmacokinetics bridging study.
About 31% of patients with recalcitrant alopecia areata totalis or universalis had complete hair regrowth.
Results showed a significantly greater proportion of patients treated with tapinarof cream achieved vIGA-AD success compared with vehicle cream.
Furthermore, from 2016 to 2018, tap water scald burns cost $206.7 million in direct health care costs
The sBLA is supported by data from Studies A and B of phase 3 LIBERTY-CUPID trial which included patients with CSU who were inadequately controlled on standard-of-care H1 antihistamines.
The application is supported by data from the pivotal phase 3 B-SIMPLE4 study which included 891 patients 6 months of age and older with molluscum contagiosum.
Delgocitinib cream is a topical pan-Janus kinase (JAK) inhibitor.
The approval was based on data from previous studies that included 124 adolescent patients, as well as the phase 3 JADE TEEN study.
However, more frequent headache, dizziness, constipation, increased urine output seen for patients receiving difelikefalin versus placebo
Belimumab is a B-lymphocyte stimulator-specific inhibitor.
18.9 percent of children and 25.7 percent of adults had seasonal allergy; 10.8 and 7.3 percent had eczema in 2021
The guidelines were developed by a multidisciplinary workgroup.
The table provided is a review of notable updates that occurred in December 2022 for investigational products in development.
December 2022 Notable Drug Approvals